|

Microbiome in Cancer Patients With High Dose Chemotherapy With Stem Cell Transplantation

RECRUITINGN/ASponsored by National Cancer Institute, Slovakia
Actively Recruiting
PhaseN/A
SponsorNational Cancer Institute, Slovakia
Started2021-03-01
Est. completion2025-12
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT04691284

Summary

Numerous in vitro and animal studies as well as growing number of clinical studies support the important role of microbiome in carcinogenesis and cancer treatment. Detection of changes in patients´ microbiome following hematopoietic cell transplantation/CAR-T cell therapy and correlations with adverse transplant outcomes, mainly infectious complications, acute and chronic GvHD, disease recurrence etc. could serve as predictive markers of immune recovery and treatment response.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* signed written informed consent
* aged 18 years or older
* patients planned to be treated by high-dose chemotherapy and hematopoietic cell transplantation or by CAR-T cell therapy in National Cancer Institute, Slovakia

Exclusion Criteria:

\- patients not-matching inclusion criteria

Conditions2

CancerHematologic Neoplasms

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.